| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | NEUTRAL | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 32.06▼ | 32.10▼ | 32.08▼ | 29.13▲ | 30.02▲ |
| MA10 | 32.10▼ | 32.04▼ | 32.12▼ | 28.56▲ | 28.45▲ |
| MA20 | 32.11▼ | 32.14▼ | 31.03▲ | 29.67▲ | 32.20▼ |
| MA50 | 32.07▼ | 29.95▲ | 28.31▲ | 28.56▲ | 32.25▼ |
| MA100 | 32.21▼ | 28.41▲ | 29.06▲ | 33.16▼ | 24.66▲ |
| MA200 | 31.17▲ | 29.16▲ | 29.84▲ | 34.54▼ | 18.52▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.019▼ | -0.171▼ | -0.049▼ | 0.259▲ | -0.336▼ |
| RSI | 37.591▼ | 56.910▲ | 64.987▲ | 61.213▲ | 50.218▲ |
| STOCH | 37.954 | 63.865 | 51.237 | 45.070 | 47.608 |
| WILL %R | -100.000▼ | -59.091 | -32.110 | -14.418▲ | -41.917 |
| CCI | -148.807▼ | -56.751 | 7.363 | 132.240▲ | 2.474 |
|
Thursday, May 14, 2026 05:58 AM
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial ...
|
|
Wednesday, May 13, 2026 12:27 AM
US biotech Rigel Pharmaceuticals is betting heavily on the newly-approved breast cancer therapy Veppanu (vepdegestrant), agreeing to pay Pfizer and Arvinas up to $405 million for global rights to the ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 14/05/26 | 32.61 | 32.9799 | 31.335 | 31.92 | 450,657 |
| 13/05/26 | 30.22 | 33.01 | 29.655 | 32.13 | 918,622 |
| 12/05/26 | 27.97 | 31.235 | 27.97 | 29.37 | 1,230,839 |
| 11/05/26 | 26.00 | 26.50 | 25.45 | 26.20 | 377,019 |
| 08/05/26 | 26.24 | 26.96 | 26.00 | 26.04 | 299,364 |
| 07/05/26 | 26.68 | 26.68 | 25.94 | 26.24 | 349,981 |
| 06/05/26 | 28.70 | 29.9999 | 25.76 | 26.67 | 849,650 |
| 05/05/26 | 29.54 | 30.0603 | 27.70 | 28.09 | 467,036 |
| 04/05/26 | 29.40 | 30.37 | 29.40 | 29.54 | 253,568 |
| 01/05/26 | 29.01 | 29.59 | 28.79 | 29.40 | 197,084 |
|
|
||||
|
|
||||
|
|